Journal Article

Mini Review Immunological Consequences of Immunization With COVID-19 mRNA Vaccines: Preliminary Results

Mangioni, Davide, Muscatello, Antonio, Bandera, Alessandra, Bozzi, Giorgio, Lombardi, Andrea, Gori, Andrea, Ungaro, Riccardo, Villa, Simone, Castelli, Valeria

2021

Overview

Background: BNT162b2 and mRNA-1273 are the two recently approved mRNA-based vaccines against COVID-19 which has shown excellent safety and efficacy. Preliminary data about specific and neutralizing antibodies is available covering the first 100 days after vaccination. Methods: We reviewed all the publications regarding the immunologic consequences of BNT162b2 and mRNA-1273 vaccination. A summary of specific antibodies concentration and neutralizing antibodies titers elicited by each vaccine is provided. Results: BNT162b2 and mRNA-1273 displayed a reassuring safety and efficacy profile, with the latter above 94%. They can elicit specific antibodies titers and neutralizing antibodies concentrations that are far superior from those observed among COVID-19 human convalescent serum, across a wide span of age, for at least 100 days after vaccination. Moreover, the vaccine-induced T cellular response is oriented toward a T H 1 response and no evidence of vaccine-enhanced disease have been reported. Discussion: BNT162b2 and mRNA-1273 can elicit specific antibodies titers and neutralizing antibodies concentrations above those observed among COVID-19 human convalescent serum in the first 100 days after vaccination. Data about vaccine efficacy in those with previous COVID-19 or immunocompromised is still limited.

• Publisher: Frontiers Media SA,Frontiers Media S.A
• Subject: 2019-nCoV Vaccine mRNA-1273 / Age groups / Animals / Antibodies / Antibodies, Neutralizing - blood / Antibodies, Viral - blood / BNT162 Vaccine / COVID-19 / COVID-19 - blood / COVID-19 - immunology / COVID-19 - prevention & control / COVID-19 - virology / COVID-19 vaccines / COVID-19 Vaccines - adverse effects / COVID-19 Vaccines - therapeutic use / CTL / Diffusion of Innovation / Host-Pathogen Interactions / Humans / Immunity (Disease) / Immunization / Immunogenicity, Vaccine / Immunology / Infections / Lymphocytes T / mRNA / mRNA Vaccines / neutralization test / Respiratory diseases / RNA vaccine / SARS-CoV-2 / SARS-CoV-2 - genetics / SARS-CoV-2 - immunology / Severe acute respiratory syndrome coronavirus 2 / Treatment Outcome / Vaccine efficacy / Vaccines / Vaccines, Synthetic - adverse effects / Vaccines, Synthetic - therapeutic use